Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
10.21
+0.09 (0.89%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$628,100
Profits / Employee
$70,000
Market Cap
2.65B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OGN News
- 8 days ago - European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 25 days ago - US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 6 weeks ago - Organon: Valuation Discount Offset By Structural Headwinds - Seeking Alpha
- 7 weeks ago - Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) - Seeking Alpha
- 7 weeks ago - Organon & Co. (OGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Organon Reports Results for the Second Quarter Ended June 30, 2025 - Business Wire
- 2 months ago - Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025 - Business Wire
- 2 months ago - OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN - PRNewsWire